Drug-induced localized lipodystrophy
MONDO:0019553Drug-induced localized lipodystrophy is a rare, acquired, localized lipodystrophy characterized by the appearance of asymptomatic, well-demarcated, variably sized, depressed, lipoatrophic lesions secondary to subcutaneous, intradermic or intramuscular drug injection, including corticosteroids, insulin, human growth hormone and antibiotics. Skin coloration may vary from white or hypopigmented to reddish, pinkish or violaceous. Epidermal atrophy may be also present.
Also known as: lipoatrophy caused by injected drug
5 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Rare leptin disorder patients gain access to experimental drug
Disease control AVAILABLEThis program provides expanded access to REGN4461 (mibavademab) for people with rare diseases caused by deficient leptin signaling, such as generalized lipodystrophy and monogenic obesity. The drug aims to help control metabolic issues linked to these conditions. Participants rec…
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New trial tests filler for 'Ozempic Face'
Symptom relief Recruiting nowThis study tests whether Radiesse (calcium hydroxylapatite) injections can restore facial volume and improve skin quality in people who lose facial fullness from GLP-1 weight loss drugs like semaglutide. 48 adults starting GLP-1 therapy will be randomly assigned to receive either…
Phase: PHASE4 • Sponsor: Kalpna Kay Durairaj, MD, FACS • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Massive european registry launches to unlock secrets of rare fat disorder
Knowledge-focused Recruiting nowThis study is a European registry for people with lipodystrophy, a rare condition where the body loses or lacks fat tissue. Researchers will follow up to 5,000 patients over time, collecting health data and genetic information. The goal is to better understand the disease, its pr…
Sponsor: University of Ulm • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC